Dasiglucagon Injection
Dasiglucagon injection (Zegalogue) is an emergency treatment for severe hypoglycemia (dangerously low blood sugar) in people with diabetes aged 6 and older.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Dasiglucagon (Zegalogue) is a ready-to-use rescue injection for severe hypoglycemia (dangerously low blood sugar) in people with diabetes aged 6 and older. It is a newer glucagon-type drug, on the U.S. market since about 2021, that tells the liver to release its stored sugar. It is generally well tolerated as a one-time dose, though nausea, vomiting and headache are common as the person comes around. It does not replace emergency care, so call for help right after every use, even if the person wakes up, then give carbohydrates by mouth once they can swallow safely.
Clinical pearls
- Show family, teachers or coworkers where the kit is and how to give it, because severe lows usually prevent self-injection.
- No response after 15 minutes? A second dose from a new device may be given while help is on the way.
- Avoid it with pheochromocytoma (an adrenal tumor) or insulinoma (an insulin-making tumor), and expect it to fail after starvation.
- Tell emergency staff about warfarin, beta-blockers or indomethacin, since each can change this rescue’s effect on bleeding, pulse or blood sugar.
Patient information guide A plain-language walkthrough of Dasiglucagon Injection, written from its FDA label.
What Dasiglucagon Injection is used for
▾
Dasiglucagon injection is used as an emergency treatment for severe hypoglycemia (dangerously low blood sugar) in people with diabetes.
- Zegalogue (subcutaneous injection) is indicated for the treatment of severe hypoglycemia in adults and pediatric patients with diabetes aged 6 years and older
How Dasiglucagon Injection works
▾
Dasiglucagon is a glucagon receptor agonist — meaning it binds to and activates the same receptors that the body's own glucagon hormone uses. When it activates those receptors in the liver, it tells the liver to break down its stored sugar (glycogen) and release glucose into the blood, raising blood sugar levels. Because it depends on those liver glycogen stores, it will not be effective if the liver is depleted — such as in someone who has been starving or has chronic low blood sugar.
Dasiglucagon Injection dosage
▾
Zegalogue is given as a single subcutaneous (under-the-skin) injection into the lower abdomen, buttocks, thigh, or outer upper arm. It is an emergency, one-time-use medication — not a daily drug. Each device contains a single dose and cannot be reused.
- Inject as soon as severe hypoglycemia is recognized
- Call for emergency medical help immediately after giving the injection
- If there is no response after 15 minutes, a second dose from a new device may be given while waiting for emergency services
- Once the person responds, give oral carbohydrates to help replenish liver glycogen and prevent blood sugar from dropping again
Dosing details from the FDA-approved label
From the Dasiglucagon Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Adults and pediatric patients aged 6 years and older (severe hypoglycemia)
- 0.6 mg administered by subcutaneous injection into the lower abdomen, buttocks, thigh, or outer upper arm
- If there has been no response after 15 minutes, an additional 0.6 mg dose of ZEGALOGUE from a new device may be administered
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION • ZEGALOGUE autoinjector and prefilled syringe are for subcutaneous injection only. ( 2.1 ) • The dose in adults and pediatric patients aged 6 years and older is 0.6 mg. ( 2.2 ) • Administer ZEGALOGUE according to the printed instructions on the protective case label and the Instructions For Use. ( 2.1 ) • Visually inspect ZEGALOGUE prior to administration. The solution should appear clear, colorless, and free from particles. If the solution is discolored or contains particulate matter, do not use. ( 2.1 ) • Administer the injection into the lower abdomen, buttocks, thigh, or outer upper arm. ( 2.1 ) • Call for emergency assistance immediately after administering the dose. ( 2.1 ) • If there has been no response after 15 minutes, an additional dose of ZEGALOGUE from a new device may be administered while waiting for emergency assistance. ( 2.1 ) • When the patient has responded to treatment, give oral carbohydrates. ( 2.1 ) • Do not attempt to reuse ZEGALOGUE. Each device contains a single dose of dasiglucagon and cannot be reused. ( 2.1 ) 2.1 Administration Instructions ZEGALOGUE autoinjector and prefilled syringe are for subcutaneous injection only. Instruct patients and their caregivers on the signs and symptoms of severe hypoglycemia. Because severe hypoglycemia requires the help of others to recover, instruct the patient to inform those around them about ZEGALOGUE and its Instructions For Use. Administer ZEGALOGUE as soon as possible when severe hypoglycemia is recognized. Instruct the patient or caregiver to read the Instructions For Use at the time they receive a prescription for ZEGALOGUE. Emphasize the following instructions to the patient or caregiver: • Administer ZEGALOGUE according to the printed instructions on the protective case label and the Instructions For Use. • Visually inspect ZEGALOGUE prior to administration. The solution should appear clear, colorless, and free from particles. If the solution is discolored or contains particulate matter, do not use. • Administer the injection in the lower abdomen, buttocks, thigh, or outer upper arm. • Call for emergency assistance immediately after administering the dose. • If there has been no response after 15 minutes, an additional dose of ZEGALOGUE may be administered while waiting for emergency assistance.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Dasiglucagon Injection side effects
▾
The most common side effects reported with Zegalogue include:
Common side effects
- Nausea
- Vomiting
- Headache
- Diarrhea (in adults)
- Injection site pain
- Temporary rise in blood pressure or heart rate
- Dizziness or presyncope (feeling faint)
- Temporary high blood pressure, low blood pressure, slow heart rate, palpitations (heart fluttering), dizziness, or orthostatic intolerance (feeling faint when standing)
When to get medical help
- Seek emergency medical attention if signs of a severe allergic reaction occur: hives, trouble breathing, or a sudden drop in blood pressure (anaphylactic shock)
- Call for emergency help immediately after every use — even if the person starts to recover
- If blood sugar drops again after the injection, get medical help right away — this could signal an insulinoma or other condition
- Tell emergency responders if the person's blood pressure rises sharply after the injection
Serious allergic reactions — including anaphylaxis (a severe, life-threatening reaction with breathing difficulty and a sudden blood pressure drop) — have been reported with glucagon products. Seek emergency care immediately if these occur.
Dasiglucagon Injection warnings and precautions
▾
- Pheochromocytoma: Do not use Zegalogue if you have this adrenal tumor — it can trigger a severe and dangerous spike in blood pressure.
- Insulinoma: Do not use if you have this insulin-producing tumor — after an initial blood sugar rise, the tumor may release excess insulin and cause a worse hypoglycemic episode.
- Low liver glycogen stores: Zegalogue will not work effectively if the liver has too little stored sugar. This can happen with starvation, adrenal insufficiency, or chronic hypoglycemia. These patients need intravenous glucose instead.
- Severe allergic reactions: Anaphylaxis and generalized rash have been reported with glucagon products. Seek emergency medical attention at any sign of a serious allergic reaction.
Dasiglucagon Injection interactions
▾
Three important drug interactions have been identified with Zegalogue:
- Beta-blockers (e.g., metoprolol, atenolol): may cause a temporary increase in pulse and blood pressure when Zegalogue is given
- Indomethacin (an anti-inflammatory pain reliever): may blunt Zegalogue's ability to raise blood sugar — and could even trigger hypoglycemia
- Warfarin (a blood thinner): Zegalogue may enhance warfarin's anticoagulant (blood-thinning) effect, increasing the risk of bleeding
Interactions listed in the FDA-approved label
From the Dasiglucagon Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Beta-blockers: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given ZEGALOGUE.
- Indomethacin: In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may even produce hypoglycemia.
- Warfarin: ZEGALOGUE may increase the anticoagulant effect of warfarin.
Read the label’s full interactions text
7 DRUG INTERACTIONS Table 3. Clinically Significant Drug Interactions with ZEGALOGUE Beta-Blockers Clinical Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given ZEGALOGUE. Indomethacin Clinical Impact: In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may even produce hypoglycemia. Warfarin Clinical Impact: ZEGALOGUE may increase the anticoagulant effect of warfarin. • Beta-blockers: Patients taking beta-blockers may have a transient increase in pulse and blood pressure. ( 7 ) • Indomethacin: In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may produce hypoglycemia. ( 7 ) • Warfarin: ZEGALOGUE may increase the anticoagulant effect of warfarin. ( 7 )
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Dasiglucagon Injection
▾
- Do not use if you have a pheochromocytoma (adrenal tumor) — contraindicated due to risk of severe blood pressure increase
- Do not use if you have an insulinoma (insulin-secreting pancreatic tumor) — contraindicated due to risk of rebound severe hypoglycemia
- May be ineffective in people with starvation, adrenal insufficiency, or chronic hypoglycemia — liver glycogen stores may be too low
- Pregnancy: No human data on safety; untreated severe hypoglycemia during pregnancy can be dangerous — discuss with your doctor
- Breastfeeding: No data on presence in breast milk; as a peptide, it is unlikely to harm a breastfed infant, but consult your doctor
- Children under 6: Safety and effectiveness not established
- Adults 65 and older: Limited clinical data available — follow prescriber's guidance carefully
- Tell your doctor about all medications you take, especially beta-blockers, indomethacin, or warfarin
Dasiglucagon Injection overdose
▾
If too much dasiglucagon is given, symptoms may include nausea, vomiting, slowed gut movement, and increases in blood pressure and heart rate. Potassium levels in the blood may drop and should be monitored and corrected if needed. Supportive medical treatment should be given based on the person's symptoms, and a doctor should be consulted right away.
What Dasiglucagon Injection does in the body
▾
After a subcutaneous injection of Zegalogue in adults with type 1 diabetes, blood glucose rose by an average of 168 mg/dL above baseline within 90 minutes. In children and teenagers (ages 7–17) with type 1 diabetes, blood glucose rose by an average of 162 mg/dL within 60 minutes. At doses far exceeding the recommended therapeutic amount, Zegalogue does not cause clinically significant changes in heart electrical activity (QT interval prolongation).
How your body processes Dasiglucagon Injection
▾
After a subcutaneous injection, Zegalogue is absorbed quickly — peak blood levels are reached in about 35 minutes in adults and about 21 minutes in children. The drug has a short half-life of approximately 30 minutes, meaning it is cleared from the body relatively fast. Dasiglucagon is broken down through the same natural pathways as the body's own glucagon — via protein-degrading enzymes in the blood, liver, and kidneys — and is not eliminated through a single organ.
How to store Dasiglucagon Injection
▾
Store ZEGALOGUE in a refrigerator, 2°C to 8°C (36°F to 46°F). Keep away from the cooling element. Do not freeze.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Dasiglucagon Injection
239 supplements and herbal products have documented interactions with Dasiglucagon Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 1
- Moderate · 208
- Minor · 30
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Dasiglucagon Injection has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Dasiglucagon Injection: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Dasiglucagon Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is Zegalogue actually for? Is it something I take every day?
▾
How do I — or someone with me — actually give this injection?
▾
What do I do if the injection doesn't seem to be working?
▾
What side effects should I expect after using Zegalogue?
▾
Are there any conditions or medications that mean I shouldn't use Zegalogue?
▾
Can I use Zegalogue if I'm pregnant or breastfeeding?
▾
Is Dasiglucagon Injection available over the counter?
▾
When was Dasiglucagon Injection first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Dasiglucagon Injection on HelloPharmacist
Dasiglucagon Injection forms and strengths (how it comes)
Dasiglucagon Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Zegalogue is used to treat severe hypoglycemia in adults and children with diabetes aged 6 years and older
- Zegalogue is available as both an autoinjector and a prefilled syringe for subcutaneous (under-the-skin) injection
- Zegalogue autoinjector and prefilled syringe are for subcutaneous injection only — inject into the lower abdomen, buttocks, thigh, or outer upper arm
- Zegalogue is a single-dose device; do not attempt to reuse it — each device delivers one dose
- Zegalogue should be inspected before use — the solution must be clear, colorless, and free of particles; do not use if discolored or cloudy
- After giving Zegalogue, call for emergency assistance immediately; if no response after 15 minutes, a second dose from a new Zegalogue device may be given while help is on the way
Dasiglucagon Injection on the U.S. market: products, makers and brands
How Dasiglucagon Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 2 Dasiglucagon Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2021. Brand names on the directory include Zegalogue; the rest are generics.
How widely Dasiglucagon Injection is used (Medicaid data)
A general measure of how commonly Dasiglucagon Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Dasiglucagon Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Dasiglucagon Injection prescribed? Of the 1,601 medications we measure, Dasiglucagon Injection ranks #1,144 by Medicaid prescriptions — more than 29% of them.
Utilization by Dasiglucagon Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
0.6 ML dasiglucagon 1 MG/ML Auto-Injector Most dispensed
Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2535247
0.6 ML dasiglucagon 1 MG/ML Prefilled Syringe
Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2535238
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Dasiglucagon Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 7 listed Dasiglucagon Injection NDCs with Medicaid activity.
Compare Dasiglucagon Injection products
A representative set of FDA-listed product records for Dasiglucagon Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 0.6 mg/0.6 mL | Subcutaneous | Novo Nordisk × 2 listings | NDA | View NDC → |
Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Dasiglucagon Injection NDCs →
Dasiglucagon Injection side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Dasiglucagon Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Dasiglucagon Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Dasiglucagon Injection FDA approval history
How Dasiglucagon Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Dasiglucagon Injection recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Dasiglucagon recalls since July 2021.
✅No Dasiglucagon recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2535233 2 dose forms · 2 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 2535246In current FDA listingsClinical drug / strength (SCD) 0.6 ML dasiglucagon 1 MG/MLRxCUI 2535247 -
Dose form (SCDF) Prefilled Syringe RxCUI 2535237No current FDA listingClinical drug / strength (SCD) 0.6 ML dasiglucagon 1 MG/MLRxCUI 2535238
Look up RxCUI 2535233 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Dasiglucagon Injection supply and shortage status
Whether Dasiglucagon Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Dasiglucagon Injection costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Injection, Solution · Subcutaneous | 0.6 mg/0.6 mL | $492.83–$493.90 per mL | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Dasiglucagon Injection brand names
Dasiglucagon Injection is sold under one brand name in the FDA directory — Zegalogue. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Dasiglucagon Injection: manufacturers and labelers
One company lists Dasiglucagon Injection products with the FDA. By number of product records, the largest are Novo Nordisk. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Dasiglucagon Injection drug class (RxNorm)
Dasiglucagon Injection belongs to the Antihypoglycemic Agent class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Dasiglucagon Injection page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Novo Nordisk is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →